CABA - Cabaletta Bio

-

$undefined

N/A

(N/A)

Cabaletta Bio NasdaqGS:CABA Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Location: 2929 Arch Street, Philadelphia, PA, 19104, United States | Website: https://www.cabalettabio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-8.147M

Cash

131.8M

Avg Qtr Burn

-23.76M

Short % of Float

12.72%

Insider Ownership

2.98%

Institutional Own.

72.40%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 1/2

Data readout

Phase 1/2

Data readout

Rese-cel (formerly CABA-201) Details
Systemic sclerosis

Big Mover™

Susp. Mover™

Phase 1/2

Data readout

Rese-cel (formerly CABA-201) Details
Immune-mediated necrotizing myopathy, Anti-synthetase syndrome, Idiopathic inflammatory myopathy / myositis, Dermatomyositis

Big Mover™

Susp. Mover™

Phase 1/2

Data readout

Rese-cel (formerly CABA-201) Details
Systemic lupus erythematosus, Lupus nephritis

Big Mover™

Susp. Mover™

Phase 1/2

Data readout

MuSK-CAART Details
Myasthenia gravis, Autoimmune disease

Phase 1

Data readout

DSG3-CAART Details
Mucosal Pemphigus Vulgaris

Phase 1

Update